8-K: Zevra Appoints Alicia Secor to Board, Wendy Dixon Retires

Zevra Therapeutics announced the appointment of Alicia Secor to its Board of Directors and the retirement of Wendy Dixon, PhD, effective December 2, 2025.

Summary

• Wendy Dixon, PhD, resigned from Zevra Therapeutics' Board of Directors and all committees, effective December 2, 2025. Her resignation was not due to any disagreement with the company.
• Alicia Secor was appointed as a Class I director, effective December 2, 2025, with her term expiring at the company's annual meeting of stockholders to be held in 2028.
• Ms. Secor will serve on the Compensation Committee and the Audit Committee of the Board.
• Ms. Secor brings over thirty years of experience in the life sciences industry, including leadership roles at Atalanta Therapeutics, Juniper Pharmaceuticals, and Genzyme.

Sentiment

Score: 7

Explanation: The filing reports a routine board transition with a highly experienced new director joining, which is generally positive for corporate governance and strategic oversight. The outgoing director's departure was amicable. No negative financial or operational news was disclosed.

Positives

• The appointment of Alicia Secor brings over 30 years of life sciences industry experience, including significant leadership in rare disease, to the Board.
• Ms. Secor's expertise is expected to support the company's continued strategy execution and commitment to delivering durable, sustained value for shareholders.
• Wendy Dixon's resignation was not due to any disagreement with the company on any matter relating to its operations, policies, or practices.

Risks

• Forward-looking statements are subject to several known and unknown uncertainties, risks, and other important factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
• The company disclaims any obligation to update such forward-looking statements at some point in the future, except as required by law, even if subsequent events cause its views to change.

Future Outlook

The company anticipates that Alicia Secor's expertise will support the continued execution of its strategy and commitment to delivering durable, sustained value for shareholders. Management believes the expectations reflected in forward-looking statements are reasonable but cannot assure that such expectations will prove correct.

Management Comments

• "We are pleased to welcome Alicia to our Board at this important juncture, as her expertise will support our continued execution of strategy and our commitment to delivering durable, sustained value for shareholders." Tamara A. Favorito, Zevra's Chair of the Board.
• "We sincerely appreciate Wendy's dedicated service and the strategic counsel she provided in advancing the Company's mission during her tenure." Tamara A. Favorito, Zevra's Chair of the Board.
• "Alicia brings a depth of experience that complements our team, including significant leadership in rare disease, and we are thrilled to welcome her to our Board." Neil F. McFarlane, Zevra's Chief Executive Officer and President.
• "I also want to thank Wendy for her leadership and wish her the very best in her retirement." Neil F. McFarlane, Zevra's Chief Executive Officer and President.

Industry Context

The appointment of Alicia Secor, with her extensive background in the life sciences industry and specific leadership in rare disease, aligns with Zevra's stated mission as a commercial-stage company focused on providing therapies for people living with rare diseases. This move strengthens the board's expertise in a specialized and growing sector of the pharmaceutical industry, where strategic execution and value delivery are critical.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of an experienced director like Alicia Secor could be viewed positively, potentially enhancing strategic oversight and governance, which may contribute to long-term shareholder value.
• Employees: A strengthened board with relevant industry expertise may provide more effective strategic direction, potentially benefiting employees through clearer company objectives and stability.

Next Steps

• Alicia Secor will serve on the Compensation Committee and Audit Committee of the Board.
• Alicia Secor's term as a Class I director will expire at the company's annual meeting of stockholders in 2028.

Key Dates

Recommendation

The filing details routine corporate governance changes with the appointment of a new, experienced director and the amicable retirement of another. While the new director's expertise in rare diseases is a positive, these changes alone are unlikely to significantly alter the company's fundamental value or near-term operational trajectory. Investors should hold their position and monitor future operational and financial reports for more impactful news.

Keywords

Zevra Therapeutics, ZVRA, Board of Directors, Alicia Secor, Wendy Dixon, Corporate Governance, Rare Disease, Biotechnology, Pharmaceuticals, Director Appointment, Director Resignation